US EditionALS Community Files Citizens’ Petition asking FDA to Approve NurOwn Stem Cell Therapy
UNITED STATES, JUL 7 – SNUG01 gene therapy targets over 90% of ALS patients and benefits from incentives including seven years of marketing exclusivity, the FDA said.
Summary by Weatherford Democrat
4 Articles
4 Articles
All
Left
2
Center
Right
1
FDA grants orphan drug status to ALS gene therapy SNUG01
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Sineugene Therapeutics‘ SNUG01, a gene therapy for people with amyotrophic lateral sclerosis (ALS). The designation is given to potential treatments for rare diseases, or those affecting fewer than 200,000 people in the U.S. It provides the company with a range of development and commercial incentives, including tax credits for clinical trials, exemption from certain f…
Coverage Details
Total News Sources4
Leaning Left2Leaning Right1Center0Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
